English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Relebactam exhibited strong potential for restoring the in vitro activity of imipenem against many RTI pathogens otherwise non-susceptible to carbapenems. Further development of this compound could provide a valuable therapeutic option for treating infections caused by resistant gram-negative bacilli from respiratory infections. Conclusions Results In Vitro Activity of Imipenem-Relebactam (MK-7655) against Enterobacteriaceae and Pseudomonas aeruginosa from Respiratory Tract Infections in North America SMART 2015 M. Hackel1, K. Young2, M. Motyl2, D. Sahm1 1IHMA, Inc., Schaumburg, IL, USA, 2MRL Merck & Co., Inc., Kenilworth, NJ, USA

open forum infectious diseases

Activity of Imipenem-Relebactam (MK-7655) Against Enterobacteriaceae and Pseudomonas aeruginosa From Intraabdominal Infections in North America—SMART 2015